绝经后激素受体阳性晚期乳腺癌内分泌治疗的研究进展

被引：8

作者：

饶彬

吴耀忠

董安慧

黄汶文

卢杰明

机构：

[1] 广西梧州市红十字会医院普外二科

来源：

中国现代医药杂志 | 2016年 / 18卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

<正>激素受体阳性乳腺癌是乳腺癌中重要的分子分型,其预后与激素受体的表达程度以及内分泌治疗选择等密切相关。上世纪70年代,三苯氧胺(TAM)的研发,使其贯穿于乳腺癌内分泌治疗的整个过程;90年代第三代芳香化酶抑制剂(AI)的面世,使其长期作为绝经后激素受体阳性晚期乳腺癌内分泌治疗的金标准;之后氟维司群的问世及研究,使得AI在这一类乳腺癌中的治疗地位受到挑战。结合内分泌治疗的临床研究证据,可以优化选择激素受体阳性

引用

页码：102 / 105

页数：4

共 6 条

[1]

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer..R. Paridaens;L. Dirix;C. Lohrisch;L. Beex;M. Nooij;D. Cameron;L. Biganzoli;T. Cufer;L. Duchateau;A. Hamilton;J. P. Lobelle;M. Piccart;.Annals of Oncology.2003,

[2]

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].

Finn, Richard S. ;

Crown, John P. ;

Lang, Istvan ;

Boer, Katalin ;

Bondarenko, Igor M. ;

Kulyk, Sergey O. ;

Ettl, Johannes ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav ;

Thummala, Anu R. ;

Voytko, Nataliya L. ;

Fowst, Camilla ;

Huang, Xin ;

Kim, Sindy T. ;

Randolph, Sophia ;

Slamon, Dennis J. .

LANCET ONCOLOGY, 2015, 16 (01) :25-35

[3]

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial [J].

Johnston, Stephen R. D. ;

Kilburn, Lucy S. ;

Ellis, Paul ;

Dodwell, David ;

Cameron, David ;

Hayward, Larry ;

Im, Young-Hyuck ;

Braybrooke, Jeremy P. ;

Brunt, A. Murray ;

Cheung, Kwok-Leung ;

Jyothirmayi, Rema ;

Robinson, Anne ;

Wardley, Andrew M. ;

Wheatley, Duncan ;

Howell, Anthony ;

Coombes, Gill ;

Sergenson, Nicole ;

Sin, Hui-Jung ;

Folkerd, Elizabeth ;

Dowsett, Mitch ;

Bliss, Judith M. .

LANCET ONCOLOGY, 2013, 14 (10) :989-998

[4]

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study [J].

Campone, Mario ;

Bachelot, Thomas ;

Gnant, Michael ;

Deleu, Ines ;

Rugo, Hope S. ;

Pistilli, Barbara ;

Noguchi, Shinzaburo ;

Shtivelband, Mikhail ;

Pritchard, Kathleen I. ;

Provencher, Louise ;

Burris, Howard A., III ;

Hart, Lowell ;

Melichar, Bohuslav ;

Hortobagyi, Gabriel N. ;

Arena, Francis ;

Baselga, Jose ;

Panneerselvam, Ashok ;

Heniquez, Aurelia ;

El-Hashimyt, Mona ;

Taran, Tetiana ;

Sahmoud, Tarek ;

Piccart, Martine .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (12) :2621-2632

[5]

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study [J].

Robertson, John F. R. ;

Lindemann, Justin P. O. ;

Llombart-Cussac, Antonio ;

Rolski, Janusz ;

Feltl, David ;

Dewar, John ;

Emerson, Laura ;

Dean, Andrew ;

Ellis, Matthew J. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) :503-511

[6]

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial [J].

Mauriac, Louis ;

Romieu, Gilles ;

Bines, Jose .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (01) :69-75

← 1 →